Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125474951 | 12547495 | 1 | I | 201511 | 20160707 | 20160712 | 20160712 | EXP | FR-ROCHE-1791718 | ROCHE | 66.00 | YR | M | Y | 70.00000 | KG | 20160712 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125474951 | 12547495 | 1 | PS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 103705 | 663.75 | MG | SOLUTION FOR INFUSION | /cycle | |||||||
| 125474951 | 12547495 | 2 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 0 | 708 | MG | INFUSION | /cycle | |||||||
| 125474951 | 12547495 | 3 | SS | DOXORUBICINE | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 0 | 44.25 | MG | INFUSION | /cycle | |||||||
| 125474951 | 12547495 | 4 | SS | Vincristine | VINCRISTINE | 1 | Intravenous (not otherwise specified) | 0 | 1 | MG | INFUSION | /cycle | |||||||
| 125474951 | 12547495 | 5 | C | ARANESP | DARBEPOETIN ALFA | 1 | Unknown | LONG-TERM TREATMENT | 0 | 150 | UG | /wk | |||||||
| 125474951 | 12547495 | 6 | C | NOVORAPID | INSULIN ASPART | 1 | Subcutaneous | LONG-TERM TREATMENT | 0 | BID | |||||||||
| 125474951 | 12547495 | 7 | C | LANTUS | INSULIN GLARGINE | 1 | Subcutaneous | LONG-TERM TREATMENT | 0 | QD | |||||||||
| 125474951 | 12547495 | 8 | C | TRAMADOL. | TRAMADOL | 1 | Oral | LONG-TERM TREATMENT | 0 | 100 | MG | BID | |||||||
| 125474951 | 12547495 | 9 | C | INEXIUM | ESOMEPRAZOLE | 1 | Oral | LONG-TERM TREATMENT | 0 | 40 | MG | QD | |||||||
| 125474951 | 12547495 | 10 | C | ZELITREX | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | LONG-TERM TREATMENT | 0 | 500 | MG | QD | |||||||
| 125474951 | 12547495 | 11 | C | PROPRANOLOL | PROPRANOLOLPROPRANOLOL HYDROCHLORIDE | 1 | Oral | LONG-TERM TREATMENT | 0 | 160 | MG | QD | |||||||
| 125474951 | 12547495 | 12 | C | ALDACTONE | SPIRONOLACTONE | 1 | Oral | LONG-TERM TREATMENT | 0 | ||||||||||
| 125474951 | 12547495 | 13 | C | LASILIX | FUROSEMIDE | 1 | Oral | LONG-TERM TREATMENT | 0 | 40 | MG | BID | |||||||
| 125474951 | 12547495 | 14 | C | LOVENOX | ENOXAPARIN SODIUM | 1 | Subcutaneous | LONG-TERM TREATMENT; 4000 IU ANTI-XA/0.4 ML | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125474951 | 12547495 | 1 | B-cell lymphoma |
| 125474951 | 12547495 | 2 | B-cell lymphoma |
| 125474951 | 12547495 | 3 | B-cell lymphoma |
| 125474951 | 12547495 | 4 | B-cell lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125474951 | 12547495 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125474951 | 12547495 | Decreased appetite | |
| 125474951 | 12547495 | Hypovolaemic shock | |
| 125474951 | 12547495 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125474951 | 12547495 | 1 | 201511 | 0 | ||
| 125474951 | 12547495 | 2 | 201511 | 0 | ||
| 125474951 | 12547495 | 3 | 201511 | 0 | ||
| 125474951 | 12547495 | 4 | 201511 | 0 |